Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TC2N

Author:

Yang Zhao1,Zhang Hongchuan2,Xia Xiaohui1,Zhang Jiangwei1ORCID

Affiliation:

1. Department of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing 402160, China

2. Department of Oncology, Dianjiang People's Hospital of Chongqing, Chongqing 408300, China

Abstract

AbstractIdentification of cytotoxic T lymphocyte (CTL) epitopes from tumor related antigens is a promising approach for malignant tumor immunotherapy. TC2N, a recently identified tumor associated antigen from human glioblastoma, is regarded as a promising target of tumor-specific immunotherapy. As one of the most widely used histocompatibility molecules in Chinese is HLA-A*0201, we were able to identify the TC2N peptides that are provided by this molecular type. A panel of antigenic peptides produced from TC2N were predicted by using a computer tool. The binding affinities of three peptides with the highest predicted score to the HLA-A*0201 molecule were evaluated after synthesis. In vitro and in vivo stimulation of the main T-cell response against the predicted peptides. The results demonstrated that TC2N (152-160) was able to release IFN-γ and lyse U251 cells in vitro as well as in vivo by eliciting peptide-specific CTLs. Our results indicated that peptide TC2N (152-160) (RLYGSVCDL) was a novel HLA-A2.1-restricted CTL epitope capable of inducing TC2N specific CTLs in vitro. As TC2N might qualify as a viable target for immunotherapeutic approaches for patients with GBM, we speculated that the newly identified epitope RLYGSVCDL would be of potential use in peptide-based, cancer-specific immunotherapy against GBM.

Funder

Chongqing Science and Health Project

Publisher

Akademiai Kiado Zrt.

Reference28 articles.

1. DNA vaccine for cancer immunotherapy;Yang B,2014

2. Emerging trends in the immunotherapy of pancreatic cancer;Banerjee K,2018 Mar 28

3. Recent development and clinical application of cancer vaccine: targeting neoantigens;Pan RY,2018 Dec 19

4. Tumor cell lysates as immunogenic sources for cancer vaccine design;González FE,2014

5. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers;Salmaninejad A,2016 Oct

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3